Screening for Fetal Anemia Using Middle Cerebral Artery Doppler

Rationale for Using the MCA

• The Society for Maternal‑Fetal Medicine recommends MCA peak systolic velocity (MCA‑PSV) as the primary Doppler screening tool for fetal anemia of any cause (e.g., alloimmunization, viral infection, twin‑twin transfusion, fetomaternal hemorrhage) because it directly reflects fetal hemoglobin status, whereas umbilical artery Doppler assesses placental resistance and does not reliably indicate anemia. 1

Diagnostic Performance

• MCA‑PSV detects moderate‑to‑severe fetal anemia with an estimated sensitivity approaching 100 % (95 % CI 0.86–1.00) and a false‑positive rate of roughly 12 %, providing a highly accurate non‑invasive screen. 1
• An MCA‑PSV threshold > 1.5 multiples of the median (MoM) identifies fetuses at significant risk for severe anemia and should trigger fetal blood sampling and preparation for possible intra‑uterine transfusion. 1
• Serial MCA‑PSV measurements (trend analysis) reduce the false‑positive rate to < 5 % compared with a single measurement, enhancing specificity. 1

Physiologic Basis

• As fetal hemoglobin falls, compensatory hyperdynamic circulation raises MCA‑PSV, allowing a reasonably accurate estimation of hemoglobin concentration in moderate‑to‑severe anemia. 1
• The MCA‑PSV technique is applicable across all etiologies of fetal anemia, making it a versatile universal screening method. 1

Standardized Measurement Technique

• Anatomical location: Measure the proximal MCA about 2 mm distal to its origin from the internal carotid artery; this site yields excellent reproducibility (intraclass correlation 0.98–0.99).
• Imaging plane: Obtain an axial view of the fetal head at the level of the sphenoid bones to visualize the circle of Willis with color Doppler, ensuring the entire MCA length occupies > 50 % of the image after zooming. 1
• Beam alignment: Align the ultrasound beam as close to 0° as possible, parallel to the artery along its full length, and avoid angle correction. 1
• Fetal state: Acquire Doppler recordings during fetal quiescence (no breathing or movements) to minimize heart‑rate‑related velocity variability. 1
• Replication: Perform at least three consecutive MCA‑PSV measurements and record the highest value for clinical decision‑making. 1

Clinical Implementation

• The complete MCA‑PSV examination requires approximately 5–10 minutes when performed by a trained sonographer. 1
• Proper training is essential; inexperienced operators may produce misleading results, so patients at risk for anemia should be referred to centers with certified sonographers.

All statements are based on evidence cited from the American Journal of Obstetrics and Gynecology (2015) and reflect the recommendations of the Society for Maternal‑Fetal Medicine.

Middle Cerebral Artery Peak Systolic Velocity as the Primary Screening Tool for Fetal Anemia

Guideline Recommendations

• The Society for Maternal‑Fetal Medicine recommends using middle cerebral artery peak systolic velocity (MCA‑PSV) as the primary screening method for fetal anemia of any etiology (e.g., red‑cell alloimmunization, parvovirus infection, twin‑twin transfusion, fetomaternal hemorrhage). 2, 3, 4

Diagnostic Performance

• A single MCA‑PSV measurement detects moderate to severe fetal anemia with sensitivity approaching 100 % (95 % CI 0.86–1.0) and a false‑positive rate of about 12 %. 3, 4
• MCA‑PSV outperforms amniocentesis for anemia diagnosis; therefore amniotic‑fluid delta OD450 should not be used for this purpose. 2, 5
• The technique is universally applicable regardless of the underlying cause of anemia, providing a versatile screening tool. 3, 4

Technical Requirements for Accurate MCA‑PSV Measurement

• Location: Measure at the proximal MCA, 2 mm distal to its origin from the internal carotid artery; this site yields excellent reproducibility (intraclass correlation 0.98–0.99). 3, 4
• Beam Angle: Align the ultrasound beam as close to 0° as possible, parallel to the artery, and avoid angle correction. 2, 5, 6
• Fetal State: Acquire the Doppler trace during fetal quiescence (no breathing or movements) to minimize heart‑rate‑related velocity variation. 3, 4
• Repetition: Perform at least three consecutive measurements and record the highest MCA‑PSV value for clinical decision‑making. 4, 6

Diagnostic Threshold

• An MCA‑PSV > 1.5 multiples of the median (MoM) signals a significant risk of severe fetal anemia and warrants fetal blood sampling with preparation for possible intra‑uterine transfusion. This threshold has been validated across multiple studies and anemia etiologies. 2, 5

Comparison with Umbilical Artery Doppler

• Umbilical artery Doppler does not reliably reflect fetal anemia because its velocity changes are not consistently related to hemoglobin levels; it primarily assesses placental resistance and is used for conditions such as placental insufficiency and growth restriction. 3

False‑Positive Rates

• Even with optimal technique, approximately 10 % of elevated MCA‑PSV results are false positives (i.e., fetuses are not severely anemic). 7
• Earlier data report a 12 % false‑positive rate when using a single MCA‑PSV measurement, consistent with the high sensitivity of the method. 3, 4

Screening and Diagnosis of Fetal Anemia

Primary Screening Method – Middle Cerebral Artery Peak Systolic Velocity (MCA‑PSV)

• MCA‑PSV Doppler is the recommended first‑line screening tool for fetal anemia in any pregnancy identified as at‑risk (e.g., alloimmunization, parvovirus infection, twin‑twin transfusion syndrome, fetomaternal hemorrhage, placental insufficiency). Fetal blood sampling is reserved for confirmation only when the MCA‑PSV exceeds 1.5 multiples of the median (MoM). 8

Diagnostic Performance of MCA‑PSV

• The technique achieves near‑perfect sensitivity for detecting moderate‑to‑severe fetal anemia (≈ 100 %; 95 % CI 0.86–1.00), indicating a very high level of evidence for ruling‑in disease. 9
• With a single MCA‑PSV measurement, the false‑positive rate is about 12 %; serial (trend) measurements lower this to < 5 %, improving specificity. 9, 10
• A pooled meta‑analysis reported an overall sensitivity of 75.5 % and specificity of 90.8 % for identifying severe anemia, supporting moderate‑to‑high quality evidence. 9

Critical Threshold for Intervention

• An MCA‑PSV > 1.5 MoM signals a significant risk of severe fetal anemia and mandates proceeding to fetal blood sampling and preparation for possible intra‑uterine transfusion. 8, 9

Confirmation – Fetal Blood Sampling (Cordocentesis)

• Cordocentesis provides definitive diagnosis and should be performed when any of the following are present:

Laboratory Evaluation After Cordocentesis

• In addition to complete blood count and hemoglobin typing, TORCH serologies (toxoplasmosis, rubella, CMV, HSV, HIV, syphilis) are recommended to identify infectious contributors to anemia. 10

Techniques to Optimize MCA‑PSV Accuracy

• The ultrasound beam must be aligned as close to 0° as possible and angle correction must be avoided, because angle correction leads to overestimation of velocity. 8
• Improper technique—measuring too distal in the MCA, applying angle correction, or acquiring the Doppler trace during fetal movement—produces falsely elevated values and should be avoided. 8

Surveillance Protocols for Specific Risk Groups

Alloimmunization

• Perform fetal antigen testing (cell‑free fetal DNA for Rh‑D or amniocentesis genotyping) once the maternal antibody titer reaches the critical threshold. 10
• If the fetus is antigen‑positive, initiate weekly MCA‑PSV monitoring and repeat maternal antibody titers every 4 weeks (more frequently if titers rise or gestation advances). 9

Parvovirus B19 Exposure

• The peak risk for fetal hydrops occurs 4–6 weeks after maternal infection; therefore, weekly MCA‑PSV and ultrasound surveillance should continue for 10–12 weeks post‑exposure. 11

Twin‑Twin Transfusion Syndrome (TTTS)

• MCA‑PSV is applicable for detecting anemia in the donor twin and should be incorporated into routine TTTS monitoring. 9, 10

Unexplained Hydrops or Growth Restriction

• MCA‑PSV screening assists in uncovering occult fetal anemia from diverse etiologies in these contexts. 9, 10

Referral and Management Thresholds

• Refer to a tertiary center with expertise in invasive fetal therapy when any of the following are identified:
• Offer fetal blood sampling with preparation for intra‑uterine transfusion unless gestational age exceeds 34–35 weeks, at which point delivery risk may outweigh procedural risk. 8

Pitfalls and Confirmation of Positive Results

• Approximately 10 % of elevated MCA‑PSV readings are false positives; therefore, confirmatory cordocentesis is required before any therapeutic intervention. 9, 10

Delivery Planning

• Schedule delivery at 37–38 weeks gestation for pregnancies with a fetus at risk for anemia, unless earlier delivery is indicated by maternal or fetal complications. 8

Management of Elevated MCA‑PSV (≥1.5 MoM) in the Second Trimester

Referral and Diagnostic Confirmation

• Refer any pregnancy with second‑trimester MCA‑PSV ≥ 1.5 MoM immediately to a tertiary center experienced in invasive fetal therapy for cordocentesis and preparation for intra‑uterine transfusion. 12
• Cordocentesis is the definitive diagnostic test to confirm the presence and severity of fetal anemia before any therapeutic intervention when MCA‑PSV exceeds 1.5 MoM. 13
• A single MCA‑PSV measurement has an approximate false‑positive rate of 12 %; therefore confirmatory cordocentesis is mandatory prior to transfusion. 12

Anemia Severity Assessment

• A fetal hematocrit < 30 % is an accepted and reliable cutoff for diagnosing fetal anemia and is routinely used in clinical practice. 13

Treatment – Intra‑Uterine Transfusion (IUT)

• Perform IUT when cordocentesis confirms moderate‑to‑severe anemia, except when gestational age is ≥ 34–35 weeks, at which point delivery may be safer than the procedural risks of transfusion. 14
• Transfusion volume is calculated with standardized formulas that incorporate donor unit hematocrit, estimated fetal weight, and the desired final fetal hematocrit. 14
• Referral to a specialized center is essential because IUT requires a coordinated multidisciplinary team experienced in fetal blood sampling and transfusion techniques. 12

Timing of Subsequent Transfusions

• Re‑assessment with MCA‑PSV guides the timing of second and later transfusions; a repeat MCA‑PSV ≥ 1.5 MoM signals recurrent anemia. 12

Surveillance Protocol

• Initiate MCA‑PSV surveillance at 18–20 weeks’ gestation, when fetal blood sampling and IUT become technically feasible. 14
• After 24 weeks, conduct weekly MCA‑PSV measurements in at‑risk pregnancies, increasing frequency if values rise or other ultrasound findings suggest worsening anemia. 14

Technical Standards for MCA‑PSV Measurement

*All of the above technical recommendations are endorsed by the American College of Obstetricians and Gynecologists. 14

• Acquiring Doppler traces during fetal movement introduces heart‑rate‑related velocity variability and compromises accuracy. 14

Common Pitfalls

• Do not use amniotic fluid delta OD₄₅₀ for diagnosing fetal anemia; MCA‑PSV has replaced this outdated method. 12

Delivery Planning

• Plan delivery at 37–38 weeks’ gestation for pregnancies with a fetus at risk for anemia, unless maternal or fetal complications necessitate earlier intervention. 13

Applicability Across Etiologies

• MCA‑PSV screening is universally applicable for detecting fetal anemia regardless of cause, including red‑cell alloimmunization, parvovirus B19 infection, donor‑twin anemia in twin‑twin transfusion syndrome, and inherited hemoglobinopathies such as α‑thalassemia. 14